浙江和沐康医药科技

Hemukang Pharmaceutical is a clinical-stage biotechnology company headquartered in Hangzhou, China, focused on the discovery and development of innovative small molecule therapeutics for chronic and metabolic diseases. The company specializes in targeting high-prevalence conditions such as type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH), as well as expanding into oncology and inflammatory disorders. Their lead candidate, HMK-001, is a potent, orally bioavailable small molecule Glucagon-like peptide 1 receptor (GLP-1R) agonist designed to offer a convenient alternative to injectable GLP-1 therapies. Hemukang leverages a proprietary drug discovery platform that integrates structure-based drug design to optimize the pharmacokinetic and safety profiles of its pipeline candidates. Backed by prominent venture capital firms like Qiming Venture Partners, the company aims to deliver best-in-class treatments to address significant unmet medical needs globally.